Advisory Committee on Immunization Practices (ACIP): Mumps Work Group

Kelly L. Moore MD, MPH
Director, Tennessee Immunization Program
Chair, Mumps ACIP Work Group

ACIP Meeting June 20, 2018

Mumps Work Group: Terms of Reference

Objective

 Evaluate and propose policy options to prevent or control mumps outbreaks in the United States

Activities

- Review epidemiology of mumps in the 2-dose vaccine era, including the international experience
- Review available evidence on duration of immunity for mumps after
 2 doses of MMR and other risk factors for vaccine failure
- Review available evidence on impact of a 3rd dose of MMR vaccine for mumps outbreak control
- Evaluate programmatic implications and cost of various policy options for a 3rd dose of MMR vaccine to prevent or control mumps outbreaks

Mumps Work Group: Members

ACIP

Kelly Moore, Chair

Paul Hunter

Cynthia Pellegrini

Jose Romero

Ex Officio Members & Liaison Representatives

Carol Baker (IDSA)

Chas DeBolt (CSTE)

Shalini Desai (NACI)

Susan Even (ACHA)

Amy Groom (IHS)

Melissa Martinez (AAFP)

Dawn Nolt (AAP/COID)

Steven Rubin (FDA/CBER)

Jane Zucker (AIM)

Consultants

Huong McLean

Patricia Quinlisk

Jane Seward

Stanley Plotkin*

CDC

Mona Marin, CDC lead

Tracy Ayers

Nakia Clemmons

Carole Hickman

Manisha Patel

Paul Rota

Janell Routh

Melinda Wharton

Patricia Wodi

Fangjun Zhou

Adria Lee

Mariel Marlow

^{*}expert consultant on scientific discussions

Mumps Work Group: Activities and Outcomes, February 2017-June 2018

Timeline	Activities	Outcome
March-October 201713 WG calls4 online surveys	 Evidence assessment Mumps epidemiology 2-dose MMR vaccine impact Data on and experience with 3rd dose MMR vaccine use Critical review of published and unpublished data regarding mumps outbreaks 	 October 2017 Proposed WG recommendations ACIP recommended use of a 3rd dose of mumps-virus containing vaccine for persons in the groups identified at increased risk for mumps during an outbreak
 January-June 2018 4 WG calls 1 online survey 3 rounds of document review 	Technical consultation, discussion and feedback for the CDC guidance for use of a 3 rd dose of MMR vaccine during mumps outbreaks	 Proposed CDC guidance for use of a 3rd dose of MMR vaccine during mumps outbreaks presented to ACIP

Mumps Work Group: Next Steps

- Mumps ACIP WG accomplished its terms of reference
- Hiatus of WG activities
 - CDC will continue to monitor mumps epidemiology in the US and new scientific evidence that can inform better control of mumps
 - WG calls as needed as new information becomes available